During Monday’s Morning trade, Shares of EMC Corporation (NYSE:EMC), gained 1.26% to $28.24.
EMC Corporation, declared preliminary third-quarter 2015 results: merged revenue is predictable to be between $6.05 and $6.08 billion. GAAP earnings per weighted average diluted share is predictable to be about $0.25. Non-GAAP earnings per weighted average diluted share is predictable to be about $0.43.
In addition, Dell Inc. and EMC Corporation recently declared they have signed a definitive agreement under which Dell, together with its owners, Michael S. Dell, founder, chairman and chief executive officer of Dell, MSD Partners and Silver Lake, the global leader in technology investing, will acquire EMC Corporation, while maintaining VMware as a publicly-traded company.
EMC will discuss further details about third-quarter 2015 results during its formerly planned earnings call at 8:30 a.m. ET on Wednesday, October 21.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies, solutions, and services. It offers enterprise storage systems and software deployed in storage area networks (SAN), networked attached storage (NAS), unified storage combining NAS and SAN, object storage, and/or direct attached storage environments, in addition to provides a portfolio of backup products that support a range of enterprise application workloads.
Shares of Merck & Co. Inc. (NYSE:MRK), declined -1% to $50.44, during its current trading session.
Merck & Co., known as MSD outside the United States and Canada, recently declared the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA® (pembrolizumab) as a first-line treatment option for adults with advanced melanoma.
In addition to recent NICE recommendation for KEYTRUDA as a first-line treatment option for adults with advanced melanoma, earlier this week NICE issued final guidance recommending KEYTRUDA for the treatment of advanced melanoma after disease progression with ipilimumab. KEYTRUDA was the first medicine available through the U.K. Early Access to Medicines Scheme (EAMS), which was introduced in the U.K. in 2014 to assist patients with life-threatening or seriously debilitating conditions benefit from promising, innovative treatments before a European license has been granted.
“The availability of KEYTRUDA for first-line use in patients will be welcomed by the melanoma community,” said Gillian Nuttall, Founder of Melanoma UK. “Advanced melanoma is a very difficult disease to treat effectively and this treatment will give hope to many. We are delighted that patients will be able to access this treatment on the National Health Services and congratulate NICE on their swift decision making.”
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, CyberArk Software, Ltd. (NASDAQ:CYBR), lost -2.66%, and is now trading at $51.50.
CyberArk Software, declared that it will report its third quarter 2015 financial results after the U.S. financial markets close on Thursday, November 5, 2015.
In conjunction with this declaration, CyberArk will host a conference call on Thursday, November 5, 2015 at 5:00 p.m. Eastern Time (ET) to discuss the company’s third quarter financial results and its business outlook. To access this call, dial 888-430-8694 (U.S.) or 719-457-2689 (international).
CyberArk Software Ltd. develops, markets, and sells software-based IT security solutions that protect organizations from cyber attacks in the United States and internationally. The company offers privileged account security solution to secure, manage, and monitor privileged account access and activities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
